Combined actinomycin D and vincristine in the treatment of patients with cancer

Abstract

A combination of actinomycin D and vincristine has been used to treat 92 patients with various kinds of cancer. The best results were obtained in patients with lung cancer, with an initial response rate of 60% and an average duration of remission of over 8 months. Some patients with sarcomas and melanomas also responded for shorter periods. This regimen appeared to be harmful in some patients with breast cancer.